Nonmedication Devices in Development for the Treatment of Alzheimer's Disease

被引:0
|
作者
Sleem, Tamara [1 ]
Decourt, Boris [2 ]
Sabbagh, Marwan N. [1 ]
机构
[1] Barrow Neurol Inst, St Josephs Hosp & Med Ctr, Dept Neurol, Phoenix, AZ USA
[2] Texas Tech Univ Hlth Sci Ctr, Sch Med, Dept Pharmacol & Neurosci, Lubbock, TX USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; clinical trials; devices; treatment; DEEP BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE-STIMULATION; COGNITIVE FUNCTION; SYNAPTIC PLASTICITY; CORTEX EXCITABILITY; DOUBLE-BLIND; PHOTOBIOMODULATION; CONNECTIVITY; DEMENTIA;
D O I
10.3233/ADR-230115
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huge investments continue to be made in treatment for Alzheimer's disease (AD), with more than one hundred drugs currently in development. Pharmacological approaches and drug development, particularly those targeting amyloid-beta, have dominated the therapeutic landscape. At the same time, there is also a growing interest in devices for treating AD. This review aimed to identify and describe devices under development for AD treatment. In this review, we queried the devices that are in development for the treatment of AD. PubMed was searched through the end of 2021 using the terms "device," "therapeutics," and "Alzheimer's" for articles that report on devices to treat AD. Ten devices with 31 references were identified as actively being developed for the treatment of AD. Many of these devices are far along in development. Device-based therapies are often overlooked when evaluating treatment approaches to AD. However, many devices for treating AD are in development and some show promising results.
引用
收藏
页码:241 / 255
页数:15
相关论文
共 50 条
  • [1] Development of huperzine A and B for treatment of Alzheimer's disease
    Bai, Donglu
    PURE AND APPLIED CHEMISTRY, 2007, 79 (04) : 469 - 479
  • [2] The Potential Development Sulfonylhydrazines for the Treatment of Alzheimer's Disease
    Penketh, Philip G.
    Shyam, Krishnamurthy
    BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY, 2023, 13 (01):
  • [3] BACE inhibitors in clinical development for the treatment of Alzheimer's disease
    Panza, Francesco
    Lozupone, Madia
    Solfrizzi, Vincenzo
    Sardone, Rodolfo
    Piccininni, Carla
    Dibello, Vittorio
    Stallone, Roberta
    Giannelli, Gianluigi
    Bellomo, Antonello
    Greco, Antonio
    Daniele, Antonio
    Seripa, Davide
    Logroscino, Giancarlo
    Imbimbo, Bruno P.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2018, 18 (11) : 847 - 857
  • [4] Treatment Development for Alzheimer's Disease: How Are We Doing?
    Lyketsos, Constantin George
    GENEDIS 2018: GENETICS AND NEURODEGENERATION, 2020, 1195 : 19 - 19
  • [5] Discovery and development of donepezil hydrochloride for treatment of Alzheimer's disease
    Sugimoto, H
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 1998, 56 (04) : 320 - 327
  • [6] Development of Piperazinediones as dual inhibitor for treatment of Alzheimer's disease
    Kumar, Devendra
    Gupta, Sukesh K.
    Ganeshpurkar, Ankit
    Gutti, Gopichand
    Krishnamurthy, Sairam
    Modi, Gyan
    Singh, Sushil K.
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 150 : 87 - 101
  • [7] Discovery and development of donepezil hydrochloride for the treatment of Alzheimer's disease
    Sugimoto, H
    Yamanishi, Y
    Ogura, H
    Iimura, Y
    Yamatsu, K
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1999, 119 (02): : 101 - 113
  • [8] Diagnostic imaging devices in Alzheimer's disease
    Jelic, Vesna
    Wahlund, Lars-Olof
    EXPERT REVIEW OF MEDICAL DEVICES, 2007, 4 (04) : 475 - 487
  • [9] Treatment of Alzheimer's disease
    Klimkowicz-Mrowiec, Aleksandra
    AKTUALNOSCI NEUROLOGICZNE, 2023, 23 (04): : 145 - 150
  • [10] The treatment of Alzheimer's disease
    Ankri, J
    REVUE NEUROLOGIQUE, 2003, 159 (8-9) : 819 - 824